Monjuvi

Showing 1 posts of 1 posts found.

fdaoutsideweb

FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma

August 3, 2020
Sales and Marketing FDA, Incyte, Monjuvi, morphosys, pharma

The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …

The Gateway to Local Adoption Series

Latest content